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Lignosulfonic acid (LA), a low-cost lignin-derived polyanionic macromolecule, was exten-
sively studied for its anti-HIV and anti-HSV activity in various cellular assays, its mechanism
of viral inhibition and safety profile as potential microbicide.
Results
LA demonstrated potent inhibitory activity of HIV replication against a wide range of R5 and
X4 HIV strains and prevented the uptake of HIV by bystander CD4+ T cells from persistently
infected T cells in vitro (IC50: 0.07 – 0.34 μM).
LA also inhibited HSV-2 replication in vitro in different cell types (IC50: 0.42 – 1.1 μM) and
in rodents in vivo. Furthermore, LA neutralized the HIV-1 and HSV-2 DC-SIGN-mediated
viral transfer to CD4+ T cells (IC50:*1 μM). In addition, dual HIV-1/HSV-2 infection in T
cells was potently blocked by LA (IC50: 0.71 μM). No antiviral activity was observed against
the non-enveloped viruses Coxsackie type B4 and Reovirus type 1.
LA is defined as a HIV entry inhibitor since it interfered with gp120 binding to the cell sur-
face of T cells. Pretreatment of PBMCs with LA neither increased expression levels of cellu-
lar activation markers (CD69, CD25 and HLA-DR), nor enhanced HIV-1 replication.
Furthermore, we found that LA had non-antagonistic effects with acyclovir, PRO2000 or
LabyA1 (combination index (CI): 0.46 – 1.03) in its anti-HSV-2 activity and synergized with
tenofovir (CI: 0.59) in its anti-HIV-1 activity. To identify mechanisms of LA resistance, we
generated in vitro a mutant HIV-1 NL4.3LAresistant virus, which acquired seven mutations in
the HIV-1 envelope glycoproteins: S160N, V170N, Q280H and R389T in gp120 and K77Q,
N113D and H132Y in gp41. Additionally, HIV-1 NL4.3LAresistant virus showed cross-
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resistance with feglymycin, enfuvirtide, PRO2000 and mAb b12, four well-described HIV
binding/fusion inhibitors. Importantly, LA did not affect the growth of vaginal Lactobacilli
strains.
Conclusion
Overall, these data highlight LA as a potential and unique low-cost microbicide displaying
broad anti-HIV and anti-HSV activity.
Introduction
According to UNAIDS’ latest results, about 2.1 million new human immunodeficiency virus
(HIV) infections still occurred worldwide in 2013 [1]. Multiple studies indicate the importance
of the interaction between genital herpes simplex type 2 (HSV-2) infections and HIV-1 on the
sexual transmission in women [2–6]. The association of HSV-2 with significantly higher
amounts of HIV-1 in plasma and genital secretions suggests that antiviral treatment of solely
HSV-2 with nucleoside analogues (e.g. acyclovir) could result in a reduced replication rate of
HIV-1. Although condom use is still the best way to protect men and women against sexually
transmitted pathogens such as HIV and HSV-2, it would be of great benefit for women to
develop self-administrating topical microbicides (e.g. vaginal/rectal gels, intravaginal ring sys-
tems, suppositories, pills) containing one or more antiviral agents with an exquisite activity
against both HSV-2 and HIV-1.
At present, the HIV-1 nucleotide reverse transcriptase inhibitor (NtRTI) tenofovir (Viread)
is the most promising microbicidal compound evaluated in clinical trials so far [7]. Topically
applied gel-formulated tenofovir has been shown to reduce the sexual transmission of HIV-1
significantly by 39% overall and surprisingly also of HSV-2 by 51% [8]. However, the observed
inhibitory activities of tenofovir on HSV-2 replication by targeting the viral DNA polymerase
was only achieved at higher drug levels [9].
Acyclovir (Zovirax) is the gold standard drug for treatment of HSV infections and belongs
to a group of synthetic drugs called nucleoside analogs [10]. The compound specifically inhibits
the herpes DNA polymerase and has little effect on the host cell DNA polymerase. However,
studies proved that long-term administration of acyclovir in immunocompromised patients
could result in drug-resistant HSV strains [11]. Lisco et al. [12] demonstrated that acyclovir
can even act as an HIV-1 reverse transcriptase inhibitor in herpes virus-infected cells, while
McMahon et al. [13] found a consistent inhibition of HIV-1 in the absence of herpes viruses.
The observed activity of tenofovir and the inconsistent findings of acyclovir indicate the need
for antiviral agents targeting both viruses with equal potency. Recent insights highlight also the
emergence of acyclovir-resistant HSV strains in immunocompetent individuals treated for her-
petic keratitis or encephalitis [11].
Entry inhibitors may even have a better profile as potential microbicide candidates as they
prevent infection of the target cells already in the (vaginal/rectal) lumen. Therefore, we focus
on the low-cost molecule lignosulfonic acid (LA), which belongs to the family of lignin-derived
macromolecules, byproducts formed during the conversion of woodpulp into paper [14]. Pre-
viously published reports demonstrated that LA has some very interesting biological properties
such as long time usage as an animal feed additive due to anti-pepsin activity and protective
effects against gastric ulcer development [15, 16]. Preliminary activity of different water-soluble
lignins against certain HIV-1 isolates was reported previously [17, 18].
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Here, we report an extensive evaluation of the consistent broad-spectrum anti-HIV and
anti-HSV activity of a low molecular weight variant of LA (mw:*8000 g/mol) in various HIV
and HSV target cell lines and in vivo in a mouse model. We also demonstrate its excellent safety
profile at the cellular level and at the level of vaginal Lactobacillimicrobiota. Hereby highlight-
ing its potential use for topical microbicidal applications.
Materials and Methods
Cell lines and virus strains
The CD4+ T-lymphoma cell lines C8166, SupT1 and HUT-78 were obtained from the Ameri-
can Type Culture Collection (ATCC, Manassas, VA, USA). The MT-4 cells were a gift from
Dr. L. Montagnier (formerly at the Pasteur Institute, Paris, France)[19]. Persistently HIV-1
IIIB HUT-78 (HUT-78/IIIB) cells were generated as described earlier [20]. The B-lymphoma
cell line Raji.DC-SIGN+ was obtained from Dr. L. Burleigh (Pasteur Institute)[21]. All cells
were cultured in RPMI-1640 medium (Invitrogen, Merelbeke, Belgium) containing 10% FCS
(Hyclone, Perbio Science, Aalst, Belgium) and 1% L-glutamine (Invitrogen).
The embryonic HEK293T cells were ordered from the ATCC. TZM-bl cells [22, 23] were a
kind gift from Dr. G. Vanham (ITG, Antwerp, Belgium). Both cell lines were cultured in
DMEM supplemented with 10% FCS and 1% HEPES (Invitrogen).
Peripheral blood mononuclear cells (PBMCs) were isolated out of buffy coats from healthy
donors, derived from the blood transfusion center (Red Cross, Belgium) by density centrifuga-
tion. The cells were then cultured in RPMI-1640 medium supplemented with 10% FCS and 1%
L-glutamine. PBMCs were stimulated with 2 μg/ml phytohemagglutinin (PHA) for 3 days at
37°C, before further usage in HIV infection assays. The preparation of monocyte/macrophages
(MDM) was described previously [24].
Monocyte-derived dendritic cells (MDDCs) were generated from freshly isolated PBMCs
(cfr. supra). PBMCs were gently rotated at 4°C to form monocyte aggregates. After sedimenta-
tion of the mononuclear cell aggregates, the pellet was resuspended in RPMI medium and incu-
bated for 90 min. at 5% CO2, 37°C to allow for monocyte adherence. After the incubation
period, non-adherent cells were carefully removed by washing three times with PBS. Adherent
cells were cultured in RPMI culture medium supplemented with 25 ng/ml IL-4 and 50 ng/ml
GM-CSF (Peprotech, London, United Kingdom). Four days later, culture medium was changed
with fresh medium containing the same cytokine composition. After 6 days, IL-4 and GM-CSF
had induced differentiation of monocytes into immature MDDCs as shown by phenotypical
analysis by fluorescently labeled anti-CD1a, anti-CD14, anti-CD80, anti-CD86, anti-DC-SIGN
and anti-HLA-DR antibodies (all from BD Biosciences, Erembodegem, Belgium) (S1 Fig).
The human embryonic lung fibroblasts (HEL cells) were obtained from the ATCC and cul-
tured in MEM containing 10% FCS, 1% L-glutamine and 0.3% sodium bicarbonate
(Invitrogen).
The HIV-1 strains NL4.3 (X4), IIIB (X4) and BaL (R5) were obtained from the AIDS
Research and Reference Reagent Program (Division of AIDS, NIAID, NIH). HIV-1 strain HE
(X4/R5) was originally isolated from a Belgian AIDS patient [25]. The HIV-2 strain ROD was
obtained from the Medical Research Council (MRC, London, UK). The characterization of the
in vitro generated HIV-1 NL4.3 and IIIB strains resistant to the entry inhibitors 2G12 mono-
clonal antibody (mAb), AMD3100, enfuvirtide (T20), feglymycin (FGM) and PRO2000 were
described previously [24, 26, 27].
The HIV-1 clinical isolates (UG273, US2, BK132, ETH2220, DJ259, SE365, BZ163,
BCF-DIOUM, HH8793, BCF-KITA, BCF-06), representing different subtypes were kindly pro-
vided by Dr. J.L. Lathey (formerly at BBI Biotech Research Laboratories, Gaithersburg, MD,
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USA). Their HIV coreceptor usage was determined in our lab using U87.CD4.CXCR4 and
U87.CD4.CCR5-transfected cells, as described previously [28].
The HSV-1 KOS and HSV-2 G were used as reference laboratory HSV strains. The HSV-1
wild-type (RV-174), HSV-1 thymidine kinase-deficient (TK-) (RV-179, RV-117), HSV-2 wild-
type (RV-124, RV-24) and HSV-2 TK- (RV-129, BA19026589) clinical isolates were derived
from virus-infected individuals in Belgium. They were obtained as part of a translational
research program granted by the Belgian Ministry of Health as part of the National Cancer
Plan for the diagnosis of drug resistance in herpesviruses. The viruses were obtained and used
as approved according to the rules of Belgian equivalent of IRB (Institutional review board)
(Departement Leefmilieu, Natuur en Energie, protocol SBB219 2011/0011, and the Biosafety
Committee at the University of Leuven).
Test compounds
The polyanionic compounds LA (mw:*8000 g/mol) and dextran sulfate (mw:*5000 g/mol)
were purchased from Sigma-Aldrich (Diegem, Belgium). PRO2000 (mw:*5000 g/mol) was
kindly provided by Dr. A.T. Profy (Formerly at Indevus Pharmaceuticals Inc., Lexington, MA,
USA). Hippeastrum hybrid agglutinin (HHA; mw: 50 kDa) was obtained from EY Labs (San
Mateo, CA, USA). Griffithsin (GRFT; mw: 25.4 kDa) was kindly provided by Dr. K.E. Palmer
(University of Louisville, KY, USA). The bacterial antibiotic peptides feglymycin (FGM; mw:
1.9 kDa) and Labyrintopeptin A1 (LabyA1; mw: 2.1 kDa) were provided by Dr. R.D. Süssmuth
(Technische Universität Berlin, Germany). Acyclovir (mw: 225 g/mol) was obtained from
GlaxoSmithKline (Brentford, UK). Maraviroc (mw: 514 g/mol) and AMD3100 (mw: 830 g/
mol) were donated by Dr. G. Bridger (at that time at AnorMed, Langley, Canada). Enfuvirtide
(T20; mw: 4.5 kDa) was provided by Dr. E. VanWijngaerden (University Hospitals, Leuven,
Belgium). The mitogenic lectin PHA (mw: 128 kDa) was ordered from Sigma-Aldrich. Tenofo-
vir (mw: 287.21 g/mol) was obtained from Gilead Sciences (Foster City, CA, USA). The mAb
b12 was ordered from Polymun Scientific (Vienna, Austria).
HIV-1 replication assays in MT-4-, TZM-bl- and primary cells
The anti-HIV assays in MT-4 cells and PBMCs have been described previously [29]. MT-4
cells (1x106 cells/ml; 50 μl) were pre-incubated for 30 min. at 37°C with the test compounds in
96-well plates (Falcon, BD Biosciences). The laboratory HIV strains (HE, NL4.3, IIIB and
ROD) were added according to the 50% tissue culture infectious dose (TCID50) of the viral
stock. Cytopathicity was scored microscopically in MT-4 cells 5 days post-infection and IC50s
were calculated spectrophotometrically using MTS/PES. For the latter viability assay, the ‘Cell-
Titer96 Aqueous One Solution Proliferation Assay’ (Promega, Leiden, The Netherlands) kit
was used.
The firefly luciferase and Escherichia coli β-galactosidase expressing CD4+, CXCR4+,
CCR5+ TZM-bl cells (50 μl; 2x105 cells/ml) were resuspended in cell culture medium supple-
mented with 15 μg/ml diethylaminoethyl-dextran (DEAE-Dextran; Sigma-Aldrich, Diegem,
Belgium) and pre-incubated for 30 min. at 37°C in 96-well plates with in cell culture medium
diluted test compounds (100 μl). Next, the laboratory HIV-1 strain R5 BaL was added (50 μl)
according to the TCID50 of the viral stock. Two days post-infection, viral replication was mea-
sured by luminescence. Steadylite plus reagent (Perkin Elmer, Zaventem, Belgium) was mixed
with lyophilized substrate according to manufacturer’s guidelines. Supernatant (120 μl) was
removed and 75 μl Steadylite plus substrate solution was added to the 96-well plates. Next, the
plates were incubated in dark for 10 min. in a closed plate shaker (PHMP, Grant, Shepreth,
Cambridgeshire, UK). Finally, cell lysis was scored microscopically and 100 μl was transferred
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to white lumitrac 96-well plates (Greiner Bio-One, Frickenhausen, Germany) to measure the
relative luminescence units (RLUs) using the SpectraMax L microplate reader and Softmax Pro
software (Molecular Devices, Sunnyvale, CA, USA) with an integration time of 0.6 sec. and
dark adapt of 5 min.
Freshly isolated PBMCs were stimulated with 2 μg/ml PHA for 3 days at 37°C before further
use in anti-HIV assays. These PHA-stimulated PBMCs (200 μl; 5x105 cells/ml) were seeded in
a 48-well plate (Costar, Elscolab NV, Kruibeke, Belgium) and pre-incubated for 30 min. at
37°C with various concentrations of LA (250 μl) in the presence of 2 ng/ml interleukin (IL)-2
(Roche Applied Science, Vilvoorde, Belgium). Next, (500 μl) 1500 pg/well of HIV-1 BaL and
500 pg/well of HIV-1 clinical isolates was given and at day 3 and 6 of infection, 2 ng/ml of IL-2
was added again. Finally, 10 days post-infection, supernatant was collected for HIV-1 p24 Ag
ELISA (Perkin Elmer) according to manufacturer’s guidelines.
MDM were seeded in 48-well plates in 1 ml medium. After removal of 800 μl of medium,
250 μl of various concentrations of LA was given in triplicate. After 30 min. at 37°C, 1000 pg/
well of HIV-1 BaL was added. Three weeks post-infection, supernatant was collected and viral
replication measured using HIV-1 p24 Ag ELISA.
HIV-1 time-of-drug addition experiments
The methodology of time-of-drug addition studies was described previously [30]. Briefly, MT-
4 cells (1x106 cells/ml) were infected with HIV-1 NL4.3. The test compounds were added in a
range from 0–5 h post-infection. Afterwards, HIV-1 replication was determined by p24 HIV-1
Ag ELISA.
Virus-inactivation assay in MT-4 cells
Fifty microliter of product solution (LA low, PRO 2000, HHA, aldrithiol) at a starting concen-
tration of 100 μg/ml was incubated with 50 μl of HIV-1 NL4.3 virus stock (2,000,000 pg/ml) in
Nunc tubes (Sigma Aldrich). After 1 hour of incubation at room temperature, all virus samples
(with or without product) were diluted to 2,000 pg/ml, 1,000 pg/ml and 200 pg/ml. Subse-
quently, 100 μl aliquots of the dilutions were added to MT-4 cells (100 μl, 50,000 cells/well) in a
96-well plate. Experiments were carried out in quintuplicate. The MT-4 cells were exposed to
concentrations (dilutions) of product that were well below their IC50 values. Degree of infection
was assessed with the cellular viability MTS/PES assay after 5 days of incubation. IC50 values
were determined based on the reference values obtained with the untreated positive control.
Anti-HSV replication assays in epithelial HEL cells
The antiviral assays of HSV replication in HEL cells was described earlier [31]. Shortly, conflu-
ent cell cultures in 96-well plates were incubated with various concentrations of LA and simul-
taneously infected with 100 TCID50 of laboratory HSV strains or clinical isolates for 3 days at
37°C before viral cytopathogenic effect (CPE) was measured microscopically. The anti-HSV
activity is expressed as the IC50 (concentration required to reduce virus induced CPE by 50%).
HSV-2 time-of-drug addition studies
The time-of-drug addition experiments with HSV-2 G were performed identically as the viral
replication assays in HEL cells, but the compounds were added separately at the time of infec-
tion (0 h) and 2 h post-infection at 1 fixed concentration: LabyA1 9.6 μM; LA 0.5 μM and acy-
clovir 10 μM. After 3 days, HSV-2 induced CPE was scored microscopically.
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MDDCs HSV-2 infection assays
MDDCs were seeded in 48-well plates (12x105 cells/200 μl/well) and pre-incubated with vari-
ous concentrations of LA (250 μl/well) for 30 min. at 5% CO2, 37°C. After the incubation
period, 50 μl of 1/40 diluted HSV-2 G was added to the wells, whether or not in the presence of
compound. After 5 days of incubation, cells were harvested and processed for further flow
cytometric side-scatter analysis. Viral titers of the samples were determined in human embry-
onic lung fibroblasts [9].
HSV-2 replication assays in HIV-1 susceptible CD4+ T-lymphoma cells
The HIV-1 susceptible T-lymphoma cell lines MT-4 and C8166 (50 μl; 5x104 cells/well) were
seeded in 96-well plates and pre-incubated with various concentrations of LA (100 μl). After 30
min. at 37°C, 50 μl of 1/30-diluted HSV-2 G was added. Cytopathicity was analyzed after 3
days in MT-4 cells and after 4 days in C8166 T cells. The IC50s were calculated using MTS/PES
as described above. In the dual HIV-1/HSV-2 infection conditions, HSV-2 replication was
measured with flow cytometry using the mouse mAb anti glycoprotein B (agB.10.B.7.)
(Abcam, UK).
Gp120 virus binding assay
CD4+ SupT1 T cells (200 μl; 2.5x106 cells/ml) were mixed with 200 μl of medium/compounds
and high amounts of HIV-1 NL4.3 (100 μl; p24 of 2x106 pg/ml) for 2h on room temperature in
a conical 15 ml polypropylene tube (Falcon, BD). After 2 washing steps with PBS containing
2% FCS (PBS/FCS2%), virus binding was detected using 1/50-diluted anti-gp120 mAb NEA-
9205 (200 μl; NEN, Boston, MA, USA) or the anti-gp120 2G12 mAb (Polymun Scientific
GmbH, Austria). After an incubation of 30 min. at 4°C and 2 wash steps, 200 μl of 1/100
diluted PE-conjugated Goat-anti-Mouse (GaM-PE; Biolegend, ImTec Diagnostics NV, Ant-
werp, Belgium) or 1/50 diluted FITC-conjugated polyclonal Rabbit-anti-Human IgG/FITC
(RaH-IgG-FITC; Dako, Heverlee, Belgium) was added and incubated at the same conditions.
After washing, the samples were fixed with 300 μl of a 1% paraformaldehyde solution and ana-
lyzed by flow cytometry (FACSCalibur; BD). Aspecific binding was determined using GaM-PE
only.
CD4+ SupT1 T cells (200 μl; 2.5x106 cells/ml) were mixed with 200 μl medium or com-
pounds for 15 min. at room temperature in a conical 15 ml polypropylene tube. After 2 wash-
ing steps with PBS/FCS2%, the cells were incubated with high amounts of HIV-1 NL4.3
(100 μl; p24 of 2x106 pg/ml) for 2 h again on room temperature. After extensive washing, virus
binding was detected using the anti-gp120 mAb NEA-9205 (1/50-fold dilution in PBS/FCS2%)
and 1/100 diluted PE-conjugated Goat-anti-Mouse (GaM-PE) at incubation conditions as
described above. Finally, the samples were fixed with a 1% paraformaldehyde solution and ana-
lyzed by flow cytometry.
HIV-1 cell-cell cocultivation assay
This method was described in detail previously [20]. In brief, various concentrations of LA
(100 μl) were added in a 96-well plate along with CD4+ SupT1 T cells (1x105 cells/50 μl). The
persistently HIV-1 IIIB infected HUT-78 cells (HUT-78/IIIB) were washed to remove free viral
particles, resuspended at a density of 1x105 cells/50 μl and immediately mixed with the SupT1
T cells for 24 h at 37°C. The next day, giant cell formation was scored microscopically and
afterwards, flow cytometry was used to calculate the IC50s. The target SupT1 T cell population
was stained with PE-conjugated anti-CD28 (CD28-PE, BD) diluted in PBS/FCS2% for 30 min.
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at 4°C. After two wash steps, the cells were fixed with a 1% paraformaldehyde solution. Acqui-
sition and analysis occurred on a FACSArray flow cytometer (BD) using Windows-based FAC-
SArray System. Aspecific binding was determined using SimulTest control (IgGγ1-FITC/
IgGγ2a-PE; BD).
HIV-1/DC-SIGN capture assay
The capture assay was performed in conical polypropylene 15 ml tubes. LA, PRO2000 and
HHA (200 μl) were diluted in medium and pre-incubated with high amounts of 100 μl of HIV-
1 HE (R5/X4; p24 of*2.5x106 pg/ml) for 30 min. at 37°C before 200 μl of Raji.DC-SIGN+
cells (5x106 cells/ml) were added. After 1 h of incubation at 37°C, the cells were extensively
washed with medium and resuspended in 200 μl of freshly prepared triton buffer (Triton-
X100/PBS solution). Samples were stored at -20°C till HIV-1 p24 Ag ELISA determination.
HIV-1 transmission assay
Raji.DC-SIGN+ cells or MDDCs (5x105 cells/200 μl) were exposed to high amounts of HIV-1
HE (100 μl;*2.5x106 pg/ml of p24) for 1 h at 37°C. Test compounds were diluted in a 96-well
plate (100 μl) and pre-incubated for 30 min. with CD4+ C8166 cells (1x105 cells/50 μl). The
virus-exposed Raji.DC-SIGN cells or MDDCs were extensively washed, resuspended and
cocultivated with the C8166 cells at the same cell density for 48 h. After light microscopic eval-
uation of syncytium formation, supernatant was collected for p24 HIV-1 Ag ELISA. In addi-
tion, the cocultures with Raji.DC-SIGN+/HE and C8166 cells were washed and stained with
anti-CD4-FITC/anti-CD209-PE (both from BD) as described above. Aspecific binding was
determined using SimulTest control (IgGγ1-FITC/IgGγ2a-PE; BD).
HSV-2 transmission and subsequent replication assay
MDDCs (1x106 cells) were pre-incubated with high amounts of HSV-2 G (170 PFU) for 3 h at
5% CO2 and 37°C. Afterwards, the cells were extensively washed with PBS/FCS2% and resus-
pended at a density of 1x105 cells/50 μl in RPMI culture medium. LA (100 μl) was diluted in
RPMI culture medium and pre-incubated for 30 min. with CD4+ MT-4 cells (1x105 cells/50 μl)
in a 96-well plate before being added to the same amount of HSV-2 exposed MDDCs. Five
days after cocultivation, giant cell formation was scored microscopically and dying MT-
4-infected cells were detected by flow cytometric side-scatter analyses.
In vivo anti-HSV-2 activity of LA in infected mice
The Ethical Committee for Animal Care and Use of the University of Leuven approved all ani-
mal work (P221/2014). Animals’ guidelines and policies were in accordance with the Belgian
Royal Decree of November 14th, 1993 concerning the protection of laboratory animals and the
EU Directive 86-609-EEC for the protection of vertebrate animals used for scientific purposes.
Female adult nu-nu mice were treated topically with 50 μl of 2.5% LA, 5% acyclovir, 1%
tenofovir (all dissolved in DMSO) or placebo (just DMSO) twice daily for 5 days, starting one
day prior to infection. On the day of infection, the skin of the mice was scarificated lumbosac-
rally and subsequently exposed to a HSV-2 G suspension (500 PFU/50 μl). Development of
lesions and mortality were recorded over 25 days. Primary lesions develop at the site of inocu-
lation and the severity of the infection was given a score based on the number and size of the
lesions [9, 32]. Initially the lesions are very small (“small early lesions”) and increase in size and
number over time (“advanced lesions”). Swab samples were taken from the lesion sites at day 6
and 7 post-infection by firmly rubbing the lesions. The swabs were subsequently immersed in 3
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ml PBS and the viral titers of the samples were determined in human embryonic lung fibro-
blasts [9]. GraphPad Prism 5 was used for developing the figures and performing MannWhit-
ney U test (GraphPad Software Inc, La Jolla, CA, USA).
Lactobacillus growth assay
The Lactobacillus strains used in this study are listed in S1 Table. All strains were routinely
grown non-shaking in MRS (de Man-Rogosa-Sharpe) medium (BD Difco) at 37°C [33]. The
capacity of different Lactobacillus strains to grow in the presence of various concentrations of
LA was performed as described previously [34]. Briefly, Lactobacilli grown overnight to sta-
tionary phase (OD600nm*1.8–2.0) were used as inocula for the assay. The assay was per-
formed in 96-well plates. Sterile wells were filled with 200 μl MRS medium. About 0.5x107
colony forming units (CFUs) (1/100 of an overnight culture) were added and various concen-
trations of LA were administered. The plates were incubated without shaking for 24 h at 37°C
before the OD600nm was measured. As a negative control, each strain was grown in compound
free medium. Each of the Lactobacillus strains and components were examined in 4 replicates
and each experiment was independently performed at least 3 times.
Cellular activation marker expression
The expression of the cellular activation markers CD69 (early), CD25 (late) and HLA-DR
(very late) were measured on freshly isolated PBMCs after 3 days of incubation at 37°C with
varying concentrations of LA, PRO2000, tenofovir and PHA. Briefly, the cells were washed
with PBS/FCS2% and incubated with PerCP-conjugated anti-CD4 mAb (BD Biosciences)
together with PE-conjugated anti-CD25 mAb (BD Biosciences), anti-CD69 mAb (Biolegend)
or anti-HLA-DR mAb (BD Biosciences) for 30 min. at 4°C. In parallel, the cells were stained
with SimulTest control IgGγ1-FITC/IgGγ2a-PE (BD) for aspecific background staining. After
washing, the cells were fixed with 1% paraformaldehyde solution and analyzed with the FACS-
Calibur and Cell Quest software (BD).
Susceptibility of PBMCs for HIV-1 infection
Freshly isolated PBMCs were cultured in the presence of LA, PHA, tenofovir, PRO2000 and
acyclovir for 24 h. The next day, the cells were collected and extensively washed in cell culture
medium, before being seeded at a density of 5x105 cells/450 μl in a 48-well plate in the presence
of 2 ng/ml IL-2. Afterwards, 50 μl of HIV-1 R5 BaL (TCID50 depending on the viral stock) was
given and supernatant was collected 7 days post-infection to measure HIV-1 replication by p24
HIV-1 Ag ELISA.
LA/antiviral drug combination assays
The methodology of analysis of two-drug combinations was described earlier [29, 35]. Shortly,
IC50s of each inhibitor solely were determined in C8166 cells for HSV-2 G and TZM-bl cells
for HIV-1 R5 BaL. Afterwards, viral replication was determined using MTS/PES method in the
presence of LA in combination with acyclovir, PRO2000 and LabyA1 for HSV-2. The anti-
HIV activitiy of LA in combination with maraviroc, tenofovir and PRO2000 was determined
using the luminiscence assay. Combination indices were calculated using CalcuSyn software
(Bio-Soft, Cambridge, UK) based on the median-effect principle of Chou and Talalay [36].
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Selection of HIV-1 NL4.3LAresistant virus and genotyping of the HIV-1 env
region
HIV-1 NL4.3 was added to MT-4 cells in 24-well plates in the presence of increasing concen-
trations of LA. Every 5 days, viral replication was scored microscopically and compound con-
centration was increased when full CPE was observed. After 55 passages, HIV-1 NL4.3LAresistant
virus was collected and viral RNA was extracted from cell culture supernatants using QIAamp
Viral RNA minikit (Qiagen, Hilden, Germany). The genotyping of the env gene was deter-
mined as described earlier [37].
Results
LA has a broad-spectrum anti-HIV activity in vitro with low cytotoxicity
First, we investigated the cytotoxicity of LA in various cell types and as shown in Fig 1A, the
50% cytotoxic concentrations (CC50s) were all higher than 62.5 μM (or>500 μg/ml).
Next, the anti-HIV activity of LA against 4 laboratory-adapted strains [2 HIV-1 X4 strains
(NL4.3, IIIB), 1 R5/X4 strain (HE) and 1 HIV-2 strain (ROD)] was evaluated in MT-4 cells
with IC50s ranging from 0.20 to 0.34 μM (1.6–2.7 μg/ml) (Fig 1B). In addition, LA exhibited
also a very potent inhibitory activity in PBMCs against various HIV-1 clinical isolates, repre-
senting different subtypes (A-H) of group M and in monocytes/macrophages against HIV-1
R5 BaL. The IC50s varied between 0.07 and 0.24 μM (0.56–1.7 μg/ml) (Fig 1C). Taken together,
these results demonstrate that the antiviral activity of LA is consistent and irrespective of HIV
coreceptor tropism.
Inhibitory activity of LA on HIV-1-associated syncytium formation
HIV infection and transmission is not only characterized by free viral particles, but also by
virus-infected cells (e.g. T cells) [38]. Therefore, the antiviral activity of LA was determined
using the giant cell (syncytium) assay between persistently HIV-infected T cells (HUT-78/IIIB)
and non-infected CD4+ target T cells (SupT1 cells). The SupT1 T cells express high amounts of
CD28, while HUT-78/IIIB cells do not (data not shown) such that this marker can be used to
determine the percentage of SupT1 T cell protection, indicative for the percentage inhibition of
syncytium formation. We found that LA neutralized this process very efficiently with an IC50
of 0.23 ± 0.02 μM (1.8 ± 0.16 μg/ml) (Fig 1D).
LA is an HIV-1 entry inhibitor by interfering with viral envelope gp120
binding
To investigate the mechanism of viral inhibition of LA, time-of-drug addition experiments
were performed (Fig 2A). The polyanionic compound dextran sulfate (DS5000), a compound
known to target HIV-1 gp120 and the NtRTI tenofovir were included as reference compounds.
Inhibition of viral infection by LA was completely abrogated 1 h post-infection, while tenofovir
kept his antiviral activity up to 4 h (Fig 2A). As can be seen from Fig 2A, LA has a comparable
inhibitory profile as dextran sulfate and this finding suggests that LA acts as a HIV entry inhib-
itor. To provide additional support that LA inhibits HIV-1 entry by interacting with the viral
envelope, we performed a virus inactivation assay. As shown in S2 Table, LA had a mild effect
on virus inactivation but less compared to the control compounds HHA and aldrithiol.
Based on the time-of-drug addition experiments, we investigated if LA interfered with the
initial gp120 binding to the cell surface. Using flow cytometry, virus binding was detected with
the anti-gp120 mAb 9205 recognizing the tip of the V3-loop and the 2G12 mAb, which binds
to high-mannose type N-glycans that lie around the C4-V4 region on gp120. Similar to FGM
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(p = 0.0318) and PRO2000 (p = 0.0041), LA inhibited significantly (p = 0.0264) the binding of
HIV-1 NL4.3 to the cell surface of SupT1 T cells as detected by the 9205 mAb. Likewise, 2G12
mAb binding was reduced in the presence of LA and this effect was dose-dependent (S2 Fig).
As expected the CXCR4 antagonist AMD3100 (p = 0.9097) had no activity in the virus binding
assay (Fig 2B and S2 Fig).
When we pre-incubated the cells with the above-mentioned entry inhibitors, washed the
cells extensively and added the same amount of virus, neither LA (p = 0.1695), FGM
(p = 0.9296), PRO2000 (p = 0.1344) nor AMD3100 (p = 0.3228) was able to significantly inhibit
Fig 1. LA has a potent broad-spectrum anti-HIV activity with low, if any, cytotoxicity. (A) Concentrations up to 62.5 μM (500 μg/ml) of LA were given to
MT-4 cells, HEK293T cells and PBMCs. Cytotoxicity levels and CC50s were determined spectrophotometrically using MTS/PESmethod. (B) Dose-
dependent anti-HIV activity of LA in the CD4+ T-lymphoma cell line MT-4 against 3 laboratory HIV-1 strains (NL4.3, IIIB and HE) and 1 HIV-2 strain (ROD)
with respectively the following IC50s: 0.20 ± 0.03 μM (NL4.3), 0.22 ± 0.06 μM (IIIB), 0.22 ± 0.00 μM (HE) and 0.34 ± 0.04 μM (ROD). Mean IC50 ± SEM up to 6
independent experiments is shown. (C). Evaluation of the IC50s of LA against various clinical isolates representing different subtypes (A-H), irrespective of
HIV-1 coreceptor tropism in primary cells (PBMCs and monocyte/macrophages [MDM]). Viral replication was measured using HIV-1 p24 Ag ELISA with
exception of p27 HIV Ag ELISA for BCF-06 (group O). The IC50s for viral inhibition were as follows: 0.10 ± 0.03 μM (UG273); 0.12 ± 0.06 μM (US2);
0.20 ± 0.05 μM (BK132); 0.15 ± 0.04 μM (ETH2220); 0.19 ± 0.01 μM (DJ259); 0.19 ± 0.04 μM (SE365); 0.16 ± 0.04 μM (BZ163); 0.13 ± 0.08 μM
(BCF-DIOUM); 0.17 ± 0.08 μM (HH8793); 0.24 ± 0.07 μM (BCF-KITA); 0.07 ± 0.05 μM (BCF-06) and 0.11 ± 0.02 μM (BaL). Mean IC50s ± SEM from 2–6
independent donor experiments is shown. (D) Dose-dependent effect of LA on the giant cell (syncytia) formation between persistently HIV-1 IIIB-infected T
cells (HUT-78/IIIB) and non-infected CD4+ target SupT1 T cells. Percentage syncytia inhibition was measured by flow cytometry. Mean ± SEM of 3
independent experiments is shown.
doi:10.1371/journal.pone.0131219.g001
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the binding of HIV-1 NL4.3 to CD4. In summary, these results show that LA binds to the enve-
lope glycoproteins of HIV and presumably not to the cell surface (Fig 2C).
LA inhibits the DC-SIGN-mediated route of viral transmission
In the next set of experiments, we investigated the binding of LA to DC-SIGN, an important
attachment receptor involved in sexual transmission of HIV-1 to CD4+ T cells [39]. At the
highest concentrations tested (12.5 μM), it appeared that LA was not able to bind to the DC--
SIGN receptor, since no dose-dependent inhibition of anti-DC-SIGN mAb was observed (Fig
3A).
Secondly, we pre-incubated high amounts of the R5/X4 HIV-1 strain HE with LA,
PRO2000 or HHA prior to exposure to Raji.DC-SIGN+ cells. As shown in Fig 3B, the polyanio-
nic compounds LA and PRO2000 did not inhibit the capture of HIV-1 to DC-SIGN, while the
Fig 2. LA binds to the HIV-1 envelope glycoproteins. (A) MT-4 cells were infected with HIV-1 NL4.3 and
dextran sulfate, LA and tenofovir were given at different time points post-infection. After 5 h, viral replication
was measured using HIV-1 p24 Ag ELISA. One representative experiment out of 3 is shown. (B) The binding
of HIV-1 NL4.3 to CD4 on SupT1 T cells in the presence of LA, FGM, PRO2000 and AMD3100, was
measured using anti-gp120 9205 mAb. Mean% ± SEM of virus binding to CD4 from 2 independent
experiments is shown. *p<0.05 according to student’s T-test. (C) The cells were first pre-incubated for 15’ at
room temperature with LA, FGM, PRO2000 or AMD3100, than extensively washed and finally incubated with
virus. The binding of HIV-1 NL4.3 to CD4 on SupT1 T cells was again measured using anti-gp120 9205 mAb.
Mean% ± SEM of virus binding to CD4 from 2 independent experiments is shown.
doi:10.1371/journal.pone.0131219.g002
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carbohydrate-binding agent (CBA) HHA significantly (p = 0.0397) interfered with this
process.
As DC-SIGN+ cells are proposed to be the first host cells facilitating further infection of
CD4+ T cells in trans, we investigated if LA could inhibit the transmission of the R5/X4 HIV-1
strain HE bound to DC-SIGN to the uninfected CD4+ target T cells. At the start of cocultiva-
tion, ~66% of the viable cells are Raji.DC-SIGN/HE (DC-SIGN+/CD4-) and 28% are C8166
(DC-SIGN-/CD4+) T cells (Fig 3C, first panel). After 48 h of coculture, the infected CD4+
C8166 target T cells lost CD4 expression and died due to HIV-1 infection (second panel). LA
inhibited this process dose-dependently (third and fourth panel) with a mean IC50 of
1.09 ± 0.025 μM (8.7 ± 0.2 μg/ml), comparable to the polyanionic compound PRO2000 (IC50:
1.2 μM; data not shown). The mean IC50-value obtained with the HIV-1 p-24 Ag ELISA was
0.8 ± 0.03 μM (6.2 ± 0.26 μg/ml), which was in the same range as with MDDCs 0.2 ± 0.02 μM
(1.6 ± 0.16 μg/ml) (data not shown). The class of CBAs (e.g. HHA, griffithsin) were previously
Fig 3. LA inhibits HIV-1 DC-SIGN-related transmission to uninfected CD4+ target T cells. (A) Raji.DC-SIGN+ cells were pretreated with or without
various concentrations of LA for 30 min. The binding of PE-conjugated anti-DC-SIGNmAb (clone DCN46) was measured by flow cytometry. The bars
represent the % of anti-DC-SIGN binding relative to the untreated conditions. Mean ± SEM of 3 independent experiments is shown. (B) Effect of LA, HHA and
PRO2000 on the capture of HIV-1 strain HE (R5/X4) by DC-SIGN on Raji.DC-SIGN+ cells. HIV-1 virions were pre-incubated for 30 min. with the test
compounds before being exposed for 1h to Raji.DC-SIGN+ cells. After washing the cells, p24 HIV-1 Ag ELISA was used to quantify the amount of cell-
associated virus. Bars represent the % virus binding relative to untreated conditions. Mean ± SEM of 3 independent experiments is shown with *p<0.05,
according to Student’s T-test. (C) HIV-1 HE (R5/X4) virions were exposed to Raji.DC-SIGN+ cells for 1 h. After extensive washing, Raji.DC-SIGN/HE cells
were cocultivated with or without compound pretreated uninfected CD4+ target C8166 T cells for 48h. Cocultures were stained with PE-conjugated anti-
DC-SIGN and FITC-conjugated anti-CD4. The % of positive gated cells in the quadrants of the dot plots is given. One representative experiment out of 3 is
shown.
doi:10.1371/journal.pone.0131219.g003
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described to be potent inhibitors of this process [20, 40, 41], as no viral transmission was
observed in the presence of 0.79 μM griffithsin (data not shown).
Potent broad-spectrum anti-HSV activity of LA
First, we evaluated the broad-spectrum anti-HSV activity of LA using the CPE reduction assay
in HEL fibroblasts against various wild-type and acyclovir resistant (thymidine kinase negative
[TK-]) HSV-1 and HSV-2 strains. LA had a consistent and broad-spectrum anti-HSV activity
with an IC50 ranging between 0.42 and 0.62 μM (3.4 and 5.0 μg/ml), comparable with acyclovir
(IC50: 0.13–0.34 μM) (Fig 4A), and remained equally active against a variety of clinical mutant
TK- HSV-1 and HSV-2 strains. These mutations resulted in a more than 200-fold decrease in
antiviral activity of acyclovir (Fig 4A). Furthermore, inhibitory activity of LA was also found
against Canine herpes virus in Madin-Darby Canin Kidney (MDCK) cells with an IC50 of
0.53 ± 0.03 μM (4.2 ± 0.24 μg/ml) (data not shown).
To investigate the mechanism of action of LA on HSV-2 infection, we performed once more
time-of-drug addition experiments in HEL cells. As shown in Fig 4B, when the compounds
were added simultaneously with the virus (0 h), LA as well as the reference compounds
LabyA1 (a HSV-2 entry inhibitor) and acyclovir (a DNA polymerase inhibitor) blocked virus
infection. When given 2 h post-infection, solely acyclovir was able to inhibit viral replication,
while LA and LabyA1 lost most of their antiviral activity (Fig 4B), the latter in agreement with
a previous report [31]. These data clearly indicate that LA acts as a HSV entry inhibitor.
Previous research has indicated that besides keratinocytes HSV-2 can also infect T cells and
DCs [42–44]. Therefore, we infected two HIV-1 susceptible T-lymphoma cell lines (MT-4 and
C8166 cells) with HSV-2 G. Viral replication was revealed with flow cytometry using the mAb
anti-glycoprotein B (agB) [10.B.7]. MT-4 (73%) and C8166 (83%) were highly susceptible for
HSV-2 infection (Fig 4C). HSV-2 G replication was dose-dependently inhibited by LA in MT-
4 and C8166 T cells with an IC50 of 1.09 ± 0.05 μM (8.7 ± 0.40 μg/ml) and 0.72 ± 0.07 μM
(5.8 ± 0.56 μg/ml), respectively (Fig 4D).
In addition, we found that LA dose-dependently protected MDDCs against HSV-2 G infec-
tion with an IC50 of 0.71 ± 0.05 μM (5.7 ± 0.40 μg/ml) (Fig 4E).
LA inhibits the HSV-2 DC-SIGN-mediated route of transmission
Previous studies revealed the importance of the DC-SIGN receptor also in HSV-2 transmission
and infection [45]. In the next set of transmission assay experiments, DC-SIGN+ cells
(MDDCs), derived from buffy coats, were exposed to high amounts of HSV-2 G and after
extensive washing cocultivated with CD4+ target T cells. After 5 days of cocultivation, massive
giant cells were formed (Fig 5A, panel a). At the highest concentrations (12.5 and 2.5 μM (100
and 20 μg/ml) tested, LA inhibited microscopically HSV-2 G transmission and replication
completely, while its protective effect disappeared at 0.5 μM (4 μg/ml) (Fig 5A, panels b-d),
resulting in an IC50 of 1.1 ± 0.1 μM (8.8 ± 0.80 μg/ml). These results are in accordance with our
flow cytometry data based on forward scatter (FSC)/side scatter (SSC) changes (IC50 of
0.95 ± 0.07 μM) (7.6 ± 0.56 μg/ml) (Fig 5B) and the measured viral titers (IC50: 0.8 ± 0.2 μM)
(6.5 ± 1.7 μg/ml) (Fig 5C).
Anti-HSV-2 activity of LA in vivo
In the next set of experiments, we evaluated the anti-HSV-2 activity of LA in vivo. Female nu-
nu mice were lumbosacrally scarificated and subsequently inoculated with HSV-2. Each group
was treated topically twice daily for 5 days, starting 1 day prior to infection. At days 6 and 7
post-infection, swab samples were taken from the site of inoculation of animals that presented
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Fig 4. Broad-spectrum anti-HSV-2 activity of LA in epithelial HEL cells, MDDCs and CD4+ HIV-susceptible T cells. (A) Dose-depedent anti-HSV
activity of LA in HEL fibroblasts against wild-type HSV-1 strains [KOS (reference) and RV-174 (clinical isolate)], TK- HSV-1 strains RV-179 and RV-117
(clinical isolates)], wild-type HSV-2 strains [G (reference), RV-124 and RV-24 (clinical isolates)] and TK- HSV-2 strains (RV-129 and BA19026589 (clinical
isolates)]. The following IC50s were obtained: 0.53 ± 0.08 μM (KOS strain); 0.59 ± 0.03 μM (RV-174); 0.62 ± 0.06 μM (RV-179); 0.51 ± 0.05 μM (RV-117);
0.42 ± 0.09 μM (strain G); 0.51 ± 0.05 μM (RV-124); 0.56 ± 0.00 μM (RV-24); 0.54 ± 0.02 μM (RV-129) and 0.42 ± 0.09 μM (BA19026589). Mean ± SEM out of
2 independent experiments is shown. (B) HEL cells were infected with HSV-2 G and the compounds [LA (0.5 μM), LabyA1 (9.6 μM) and Acyclovir (10 μM)]
were added at the time of infection (0 h) or 2 h post-infection. After 3 days, virus-induced CPE was scored microscopically. Mean ± SEM up to 3 experiments
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advanced lesions or small early lesion and viral titers of the samples were determined. The
highest viral titers were observed in the placebo-arm. Treatment with a solution containing
2.5% LA (p = 0.0159) or 1% tenofovir (p = 0.0195), both dissolved in DMSO, showed signifi-
cant lower viral titers compared to the placebo after 7 days (Fig 6). Comparable results were
found on day 6 post-infection (data not shown). No viral titers were determined in the acyclo-
vir-treated group, as no lesions were observed. Based on these results we can conclude, firstly,
that acyclovir completely suppresses HSV-2 replication and secondly that LA and tenofovir
have comparable antiviral effects in vivo (Fig 6).
LA inhibits dual HIV-1 and HSV-2 infection in T cells
The previously described experiments evaluated the effect of LA on the replication of the 2
viruses separately. Next, LA was tested in a cellular HIV-1/HSV-2-co-infection model and its
antiviral activity was compared with the well-known HIV-1 entry inhibitor AMD3100 (a
CXCR4 antagonist) and the HSV-2 DNA polymerase inhibitor acyclovir. Using the MTS/PES
method, we observed that LA dose-dependently inhibited HIV-1/HSV-2 co-infection (IC50 =
0.71 ± 0.18 μM (5.7 ± 1.4 μg/ml)) to the same extent as in the single HIV-1 NL4.3 (IC50 =
0.20 ± 0.03 μM (1.6 ± 0.24 μg/ml)) or HSV-2 G (IC50 = 0.84 ± 0.16 μM (6.7 ± 1.3 μg/ml)) infec-
tion conditions, as shown in Fig 7A. Dual HIV-1 NL4.3/HSV-2 G infection was further ana-
lyzed with flow cytometry using anti-gp120 mAb b12 for HIV-1 NL4.3 and anti-gB (agB; 10.
B.7) mAb for HSV-2 G detection. These anti-HIV-1 NL4.3 (IC50 = 0.34 ± 0.18 μM
(2.7 ± 1.4 μg/ml)) and anti-HSV-2 G (IC50 = 0.50 ± 0.10 μM (4.0 ± 0.8 μg/ml)) flow cytometric
data clearly confirmed our observations obtained with the MTS/PES method.
The potent HIV-1 inhibitor AMD3100 lacked anti-HSV-2 activity (IC50>1200 nM), while
HIV-1 NL4.3 was dose-dependently inhibited with an IC50 of 18.0 ± 2.7 nM (Fig 7B). The
MTS/PES method revealed no inhibitory activity of AMD3100 in the dual HIV-1/HSV-2 infec-
tion model. However when viral replication of HIV-1 and HSV-2 was measured by flow
cytometry using the above-mentioned antibodies, the analysis clearly demonstrated that
AMD3100 inhibited solely HIV-1 replication (IC50 = 23.4 ± 5.4 nM), as the IC50 for HSV-2
was>1200 nM. On the other hand, acyclovir potently inhibited HSV-2 G replication (IC50 =
0.85 ± 0.15 μM) in T cells, while lacking anti-HIV-1 NL4.3 activity in single infection condi-
tions. In the co-infection model, no anti-HIV/HSV activity could be detected for acyclovir
(IC50>444 μM; Fig 7C) using the MTS/PES method. However, flow cytometric data indicated
that acyclovir was still able to inhibit HSV-2 replication in the latter model with an IC50 of
1.3 ± 0.9 μM, while having no anti-HIV activity (IC50>444 μM).
Lack of stimulatory effects of LA on HIV-1 target cells
To be a potential microbicidal candidate, LA may not activate HIV susceptible target cells.
Therefore, LA was thoroughly investigated for its potential cell activating properties. Here, we
used the mitogenic lectin PHA as positive control. Freshly isolated PBMCs were exposed to
various concentrations of LA, tenofovir or PHA and after 72 h, the expression of the activation
markers CD69 (early), CD25 (late) and HLA-DR (very late) on CD4+ T cells was determined
is shown. (C) Infection of HSV-2 G in CD4+ HIV-1 susceptible T cell lines. MT-4-, C8166 T-lymphoma cells were infected with HSV-2 G. Percentage of
infected cells is indicated after 3 days (MT-4 cells) or 4 days (C8166 cells) post-infection as detected using the mAb [10.B.7] directed to the HSV-2 envelope
glycoprotein B (gB) by flow cytometry. Grey histograms represent the background fluorescence, while the black histograms show virus binding. The mean
fluoresence intensity (MFI) values are indicated in each histogram. (D) Dose-dependent anti-HSV-2 G activity of LA in the CD4+ T-lymphoma cell lines MT-4
and C8166 as measured spectrophotometrically. Mean IC50 ± SEM from 5–6 independent experiments is shown. (E) Infection of HSV-2 G in MDDCs. Viral
replication was measured 5 days post-infection, relative to the postive control, based on flow cytometry side-scatter analyses. Mean ± SEM of 4 individual
donors is shown.
doi:10.1371/journal.pone.0131219.g004
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by flow cytometry. The percentage of CD4+CD69+ PBMCs in untreated conditions was
2.9 ± 0.9 (mean ± SEM). Treatment with 12.5 μM (100 μg/ml) LA (5.5 ± 1.6%; p = 0.1955) or
200 μM tenofovir (1.9 ± 0.9%; p = 0.4499) did not significantly increase the number of CD4+-
CD69+ T cells. PHA treatment (0.078 μM), on the other hand, markedly increased (11-fold)
Fig 5. LA inhibits HSV-2 DC-SIGN-related transmission to uninfected target T cells. (A) DC-SIGN+ cells were generated out of buffy coat and exposed
to HSV-2 G for 2 h. After several washing steps, virus exposed cells were cocultivated with uninfected CD4+ MT-4 cells for 5 days. Viral-induced cytopathicity
was first scored microscopically. Shown here are the light microscopic pictures of cocultivated HSV-2 G-exposed DC-SIGN+ cells and uninfected MT-4 cells
5 days post-cocultivation (a); the effects on HSV-2 G transmission and replication in the presence of 12.5 μM (b), 2.5 μM (c) and 0.5 μM LA (d). One
representative experiment out of 4 individual donors is shown. (B) Bars represent the % HSV-2 G transmission and replication in MT-4 cells after 5 days of
cocultivation, relative to the positive control. Dying MT-4 infected cells were detected by flow cytometry side-scatter analyses. Mean ± SEM out of 4 individual
donors is shown. (C) MDDCs were generated from buffy coat and exposed to HSV-2 G for 2h. After several washing steps, virus exposed MDDCs were co-
cultivated with uninfected CD4+ MT-4 cells for 5 days. Viral-induced cytopathicity was scored light microscopically and supernatant was retained for further
analysis of viral content. Bars represent the percentage of viral replication after 5 days of co-cultivation, relative to the positive untreated control. Mean ± SEM
of 3 independent experiments is shown.
doi:10.1371/journal.pone.0131219.g005
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the amount of CD4+CD69+ cells (33.0 ± 1.8%; p<0.0001) (Fig 8A, left). Compared to untreated
conditions (15.7 ± 1.8%) LA had no impact on the number of CD4+CD25+ expressing T cells
(18.7 ± 2.2%; p = 0.3251), whereas PHA dramatically increased the amount of CD4+CD25+
cells (39.8 ± 2.6%; p<0.0001) (Fig 8A, middle). In addition, LA did not affect the expression of
the very late activation marker HLA-DR. The number of CD4+HLA-DR+ cells after LA treat-
ment was almost identical to that of the negative control (5.4 ± 1.1% and 3.9 ± 0.6%,
p = 0.2557; respectively). A significant 5-fold increase (p = 0.0005) in the amount of CD4+-
HLA-DR+ T cells was observed with PHA (20.2 ± 3.2%; Fig 8A, right).
In the next set of experiments, we determined whether LA treatment of PBMCs for 24 h
influenced their susceptibility to HIV-1 infection. Freshly isolated PBMCs from 3 different
donors were pretreated with LA, tenofovir, PRO2000 or acyclovir. Once more the mitogenic
lectin PHA was included as positive control. After 24 h, the cells were extensively washed and
infected with the HIV-1 R5 strain BaL in the absence of compounds. Seven days post-infection,
HIV-1 p24 Ag production was determined in the supernatant. The p24 Ag production of
untreated cells (PC) was 1806 pg/ml (Fig 8B). Pretreatment with LA did not enhance the cellu-
lar susceptibility to HIV-1 considering its p24 Ag concentration of 2152 pg/ml, which was
comparable with another polyanionic compound PRO2000 (1947 pg/ml) and the well-known
antiviral agents tenofovir (1579 pg/ml) and acyclovir (1321 pg/ml) (Fig 8B). In contrast,
Fig 6. Effects of LA, tenofovir and acyclovir on the viral titers in mice inoculated with HSV-2 G.Groups
of five female nu-nu mice were inoculated with HSV-2 on the lumbosacral area. Each group was treated
topically two times a day for 5 consecutive days, starting 1 day prior to infection. The placebo cohort received
a similar treatment with the test formulation without compound. On day 7 post-infection, swab samples were
taken from animals that presented clear advanced lesions or small early lesions. The acyclovir group did not
develop any lesions. Mean PFU/ml-values are indicated for each group. Statistical significance compared to
placebo: *p<0.05, according to Mann-Whitney U test.
doi:10.1371/journal.pone.0131219.g006
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Fig 7. LA inhibits efficiently single and dual HIV-1/HSV-2 infection in T cells.MT-4 cells were infected with HIV-1 NL4.3, HSV-2 G and HIV-1 NL4.3
+ HSV-2 G for 3 days in the presence of various concentrations of LA (A), AMD3100 (B) and acyclovir (C). Cytopathicity was measured
spectrophotometrically using MTS/PES (left panels). The results are normalized to untreated infected cells. Viral replication at dual infection (shown in blue)
was also further investigated by flow cytometry (right panels). HIV-1 NL4.3 replication was detected with b12 mAb + RaH-FITC (white bars) and HSV-2 strain
G with agB + GaM-PE (grey bars). Bars indicate the % viral replication in MT-4 cells, compared to untreated conditions. The results shown are the
mean ± SEM of 3–5 independent experiments.
doi:10.1371/journal.pone.0131219.g007
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pretreatment with PHA led to a dramatic increase in viral replication as demonstrated in p24
Ag levels with values up to 20190 pg/ml.
No growth inhibitory effects of LA on the vaginal microbiota
The vaginal (and also gut) microbiota is very important for the health of the host and may pref-
erentially not be affected by potential microbicidal agents that would offer protection against
sexually transmitted diseases such as HIV and HSV [46]. Therefore, we investigated in detail
the effects of LA on the growth capacity of the normal vaginal microbiota, which is composed
mainly out of Lactobacillus spp. All of the tested Lactobacillus strains showed the ability to
grow in the presence of concentrations of LA as high as 31 μM (or 250 μg/ml) (Fig 9).
In general synergistic effects of LA in combination assays
An effective microbicide will presumably consist out of at least two different antiviral drugs.
Therefore, we investigated if LA acts synergistically with acyclovir, PRO2000 or LabyA1 on
Fig 8. Lack of stimulatory effects of LA on PBMCs. (A) LA does not activate HIV-1 susceptible CD4+ T cells. Freshly isolated PBMCs were cultured in the
presence of LA, tenofovir or PHA for 3 days at 37°C. The cells were then analyzed for their expression of the activation markers CD69 (early), CD25 (late)
and HLA-DR (very late) by the mAbs PE-conjugated anti-CD69 (left), anti-CD25 (middle) and anti-HLA-DR (right) together with PerCP-conjugated anti-CD4.
Mean ± SEM of 6 independent experiments is shown. ***p<0.001; ****p<0.0001, according to student’s T-test for comparison with untreated PBMCs. (B)
Freshly isolated PBMCs were pretreated with LA, tenofovir, PRO2000, acyclovir or PHA for 24h, then thoroughly washed and infected with HIV-1 R5 BaL for
7 days in the abscence of compounds. Viral replication in the supernatant was measured using HIV-1 p24 Ag ELISA. Mean of 3 independent donor
experiments is shown.
doi:10.1371/journal.pone.0131219.g008
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HSV-2 G replication in C8166 cells. As shown in Fig 10A, the IC50s of LA decreased 10-fold in
combination with acyclovir (IC50: 0.12 ± 0.02 μM (0.96 ± 0.16 μg/ml); p = 0.0089), 4-fold with
PRO2000 (IC50: 0.46 ± 0.05 μM (3.7 ± 0.4 μg/ml); p = 0.0165) or 4-fold with LabyA1 (IC50:
0.29 ± 0.01 μM (2.3 ± 0.08 μg/ml); p = 0.0183). For each combination with LA, we observed a
1.3- to 2-fold dose reduction, which was only found to be significant when LA was combined
with LabyA1 (p = 0.0027). CIs were determined to investigate the potential synergistic/addi-
tive/antagonistic effects, and as overviewed in Fig 10B, a synergistic interaction was observed
with PRO2000 and acyclovir, with the highest levels of synergy in the LA/acyclovir combina-
tion. When LA was combined with LabyA1, an additive interaction was observed at the CI50-
level, but increased synergistic effects were seen with increasing doses (CI75 and CI90).
In addition, we analyzed the effects of LA in combination with PRO2000, maraviroc or
tenofovir on HIV-1 R5 BaL replication in TZM-bl cells. A significant 3-fold decrease in its
IC50-value was observed for LA in combination with maraviroc (IC50: 0.22 ± 0.05 μM
(1.8 ± 0.40 μg/ml); p = 0.0194) or/and a 4-fold reduction with tenofovir (IC50: 0.14 ± 0.04 μM
(1.1 ± 0.32 μg/ml); p = 0.0221) (Fig 10C). Non-significant dose-reduction effects were observed
in combination with PRO2000 (p>0.05).
CI analysis revealed antagonistic to additive effects in combination with PRO2000, while
synergy was seen at each inhibitory level with tenofovir (Fig 10D). LA/maraviroc combinations
showed additivity at CI50-levels and increasing synergistic effects with increasing doses.
Inhibitory effects of LA independent on viral input levels
The amount of infectious virions at the time of transmission is not exactly known. Here, we
investigated if LA is able to inhibit HIV-1 infection and replication at increased viral inputs
(Table 1). These data clearly indicate that LA kept consistently its anti-HIV activity, with only
a 1.8-fold decrease in its IC50, even at a 50-fold higher HIV-1 NL4.3 concentration. The other
polyanionic compound PRO2000 showed a 4.5-fold decrease. Enfuvirtide (T20), used as refer-
ence compound was completely inactive at the highest concentrations tested. In addition, a
3.5-fold increase in IC50 for LA was observed with increasing concentrations of HIV-2 ROD,
while T20 lacked all anti-HIV-2 activity (data not shown).
Fig 9. No toxic effects of LA on vaginal Lactobacilli.Growth of the gastro-intestinal L. rhamnosus GG and
different vaginal Lactobacilli strains in the presence of various concentrations of LA for 24 h. The results are
expressed in % of untreated bacterial cells. The mean ± sem of 3 independent experiments is shown.
doi:10.1371/journal.pone.0131219.g009
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Fig 10. Effects of LA/antiviral drug combinations on HSV and HIV replication. (A) Effects of LA combinations on their anti-HSV-2 G activity in C8166
cells. The IC50s of LA (white bars) and the combined inhibitors acyclovir, PRO2000 and LabyA1 (grey bars), alone and in combination, are represented.
Mean ± SEM from 3 independent experiments is shown. *p<0.05, **p<0.01, according to student’s T-test, compared with single-drug treatment. (B)
Determination of the combination indices (CIs) of LA/acyclovir, LA/PRO2000 and LA/LabyA1 two-drug combinations. Mean CIs ± SEM from 3 independent
experiments is shown. The CIs were calculated at 3 inhibitory levels (IC50, IC75, IC90), whereby CIs<0.9 are synergistic, 0.9<CIs<1.1 are additive and CIs>1.1
are antagonistic. (C) Effects of LA combinations on their anti-HIV-1 R5 BaL activity in TZM-bl cells. The IC50s of LA (white bars) and the combined inhibitors
PRO2000, maraviroc and tenofovir (grey bars), alone and in combination, are represented. Mean ± SEM from 3–4 independent experiments is shown.
*p<0.05, according to student’s T-test, compared with single-drug treatment. (D) Calculation of CIs of LA in combination with PRO2000, maraviroc and
tenofovir. Mean CIs ± SEM from 3–4 independent experiments is shown. The CIs were again calculated at 3 inhibitory levels (IC50, IC75, IC90), whereby
CIs<0.9 are synergistic, 0.9<CIs<1.1 are additive and CIs>1.1 are antagonistic.
doi:10.1371/journal.pone.0131219.g010
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Selective mutations in the envelope gene of HIV-1 NL4.3LAresistant virus
We generated in vitro an NL4.3LAresistant HIV-1 strain to gain more insight in the mechanism
of action of LA. Wild-type NL4.3 was cultured in MT-4 cells in the presence of increasing con-
centrations of LA. As a control, wild-type NL4.3 virus was subcultivated in parallel in the
absence of compound. The HIV-1 NL4.3LAresistant virus acquired four mutations throughout
gp120: S160N in the V2 loop, V170N in the C2 region, Q280H in the V3 loop and R389T in
the C5 region. Two additional mixed mutations were found at R118K/R and A310A/V. In
gp41, 3 mutations were observed: K77Q adjacent to HR1 domain, N113D, which belongs to
glycosylation sequon “NXT” and H132Y inside HR2 domain. The HIV-1 NL4.3LAresistant virus
showed a 10.5-fold decrease in sensitivity to LA (Fig 11A).
Cross-resistance of HIV-1 NL4.3LAresistant virus against various HIV entry
inhibitors
As shown in Fig 11A, high levels of cross-resistance were observed with viral envelope binding
agents FGM (7-fold), T20 (>16-fold), PRO2000 (14-fold) and mAb b12 (5-fold), as shown
Table 1. Effects of antiviral activity on increased viral input in MT-4 cells.
HIV-1 NL4.3 viral inputb
25 125 250 625 1250
Agenta fold changec
LA 0.24 ± 0.02 0.30 ± 0.01 0.28 ± 0.03 0.39 ± 0.04 0.43 ± 0.06 1.8
T20 0.031 ± 0.005 0.099 ± 0.015 0.22 ± 0.05 0.75 ± 0.11 >1.1 >36
PRO2000 0.13 ± 0.03 0.39 ± 0.01 0.46 ± 0.06 0.54 ± 0.05 0.59 ± 0.02 4.5
a Concentrations are in μM.
b Viral input is expressed in pg/well, with 25 pg/well as our reference viral input.
c Fold change in IC50s: highest IC50/lowest IC50.
doi:10.1371/journal.pone.0131219.t001
Fig 11. Cross-resistance pattern of the HIV-1 NL4.3LAresistant virus. (A) Fold-increase in IC50 of the HIV-1 NL4.3
LAresistant virus against the entry inhibitors
HHA, FGM, T20, PRO2000, AMD3100 and b12 mAb. Mean ± SEM of 3–4 independent experiments is shown. (B) Dose-dependent effects of LA on the
replication of the in vitro generated HIV-1 entry inhibitor resistant strains in MT-4 cells. Mean ± SEM of 3 independent experiments is shown.
doi:10.1371/journal.pone.0131219.g011
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with increased IC50-values, while the antiviral activity of HHA and AMD3100 remained
unchanged.
LA showed no cross-resistance with various HIV entry inhibitor resistant
strains
As LA acts as an entry inhibitor, potential cross-resistance was further evaluated against 5
HIV-1 entry inhibitor resistant strains (Fig 11B) that were obtained by targeting different steps
in the HIV-1 entry process. LA inhibited the wild-type HIV-1 strains NL4.3 and IIIB with an
IC50 of, respectively, 0.20 and 0.22 μM (1.6 and 1.8 μg/ml) (Fig 1B). No significant loss in anti-
viral activity was observed against the HIV-1 strains resistant to 2G12 mAb (0.20 ± 0.00 μM
(1.8 ± 0.00 μg/ml); NL4.32G12res.), FGM (0.33 ± 0.03 μM (2.6 ± 0.24 μg/ml); HIV-1 IIIBFGMres.),
AMD3100 (0.57 ± 0.05 μM (4.6 ± 0.40 μg/ml); NL4.3AMD3100res.) and T20 (0.30 ± 0.02 μM
(2.4 ± 1.6 μg/ml); NL4.3T20res.). Only a significant*8-fold decrease (p = 0.0185) in antiviral




In this study, we investigated the antiviral activity and microbicidal properties of the novel
low-cost sulfonated polyanionic compound, lignosulfonic acid (LA).
LA demonstrated a potent and consistent broad-spectrum anti-HIV activity in the
lower μM-range with low, if any, cytotoxicity in replication and cocultivation assays (Fig 1).
These findings are in accordance with recently published data [18], where Qui and colleagues
demonstrated the binding of a sulfonated lignin to the V3 loop of gp120 [18]. This loop plays a
critical role in the entry process of HIV by interacting with the chemokine receptors CCR5
and/or CXCR4 [47]. This observation could explain its broad-spectrum anti-HIV activity
against both R5 and X4 viruses. However, in the past, many concerns have been raised as X4
and R5 HIV-1 strains differ substantially in their sensitivities to polyanionic compounds, due
to differences in positive charges [48]. As indicated for PRO2000 [49], LA inhibited equally
well X4 and R5 viruses.
HIV-1 binding experiments demonstrated that LA, just like the included reference com-
pounds FGM [24] and PRO2000 [50], significantly inhibited the initial interaction of free HIV-
1 virions to the cell surface of target CD4+ T cells (Fig 2B). These results correspond to those
obtained with other water-soluble lignins using rgp120 and sCD4 [18]. We hypothesize that
this reflects inhibition by LA of the interaction between gp120 and cellular CD4. Nevertheless,
we also need to consider the possibility that LA compromises virion binding to other T cell sur-
face molecules such as heparan sulfate proteoglycans [51]. As a washing step after pre-exposure
of the CD4+ T cells to compounds (i.e., LA, PRO2000, FGM) did not prevent virus binding, the
interaction between LA and the cell surface appears to be rather weak (Fig 2C). These findings
led us to believe that LA mainly binds to the HIV-1 envelope glycoproteins and not to the cell
surface. Nevertheless, we (data not shown) and others observed a dose dependent binding inhi-
bition of anti-CD4 mAb binding to the CD4 receptor in the presence of LA variants [18]. This
could represent an additional mode of interference with gp120-CD4 interaction. However, this
anti-CD4 mAb binding inhibition was only observed in the high LA concentration range (100–
200 μg/ml) [18].
Epitope mapping experiments using the neutralizing mAbs 2G12, targeting the N-linked
glycans on gp120; b12, recognizing the CD4 binding site on gp120; and 447-52D, binding to a
part of the V3 loop on gp120; indicated that a certain sulfonated lignin significantly inhibited
dose-dependently the antibody binding to the CD4 binding site and the V3 loop on gp120
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[18]. These findings suggest that LA interacts with multiple sites on gp120. In addition, we gen-
erated an in vitro LA-resistant HIV-1 strain. The observed mutations throughout gp120 gave
indeed another indication that LA interacts with different regions on gp120. We found that LA
is able to interfere with the CD4/gp120 binding as the V170N mutation occurred in a sequence
of the C2 region, which is part of the CD4-induced epitope [52]. The R389T substitution in the
C5 region is situated adjacent to the V4 loop and was described previously as another impor-
tant sequence involved in CD4 and mAb b12 binding [52, 53]. The mutation Q280H on the tip
of the V3 loop explains the interaction of LA with the V3 loop and this mutation was also
observed with previously reported polyanionic compounds [54]. The mutations around the
CD4 binding motifs and in the V3 loop could explain the observed cross-resistance with
PRO2000 and FGM (Fig 11), two compounds described to inhibit CD4/gp120 binding [24, 49,
50]. The moderate cross-resistance with b12 mAb, which targets the CD4-binding site on
gp120, could be explained by the observed mutation at one of the b12 mAb contact sites and a
reported inhibition of b12 mAb by a sulfonated lignin for binding to gp120 by Qui et al. [18].
The lack of 2G12 mAb binding inhibition by this lignin on gp120 [18] also corresponds with
our findings, as no high-type mannose N-linked glycans were deleted on gp120. On that
account, the mannose-specific CBA HHA kept its full antiviral activity (Fig 11) in our cross-
resistance studies. Finally, the K77Q (adjacent to HR1) and H132Y (in domain HR2) muta-
tions, both in gp41, reduced the activity of T20, the FDA-approved gp41 fusion inhibitor.
Although the cross-resistance of a LA-resistant strain to the only FDA-approved fusion inhibi-
tor might seem cumbersome, the use of T20 in daily practice is drastically reduced due to the
fact that it needs to be injected twice daily and because of the continuous emergence of T20
resistant mutations [55–57].
Previous studies highlighted the clinical importance of genital HSV-2 infections as a co-fac-
tor for increased HIV transmission in women [2, 6, 58]. We showed for the first time that LA
possessed a comparable antiviral activity (lower μM-range) against wild-type and acyclovir-
resistant HSV-1 and HSV-2 strains (Fig 4A). These observations are very important regarding
the occurrence of acyclovir-resistant strains not only in immunocompromised patients, but
also in immunocompetent individuals [11, 59]. Another important observation is that LA
could also inhibit HSV-2 infection in MDDCs, one of the key cells of the innate immune sys-
tem involved for T cell responses. Additionally, MDDCs could also contribute to viral spread
in the mucosa [60]. HSV-2 infection results in the expression and secretion of retinoic acid,
which induces the expression of α4ß7 integrin on CD4+ T cells to make them more vulnerable
for HIV-1 infection [44]. Recently, Stefanidou et al. demonstrated that HSV-2 infection pre-
vents MDDCs maturation, induce apoptosis and triggers the release of pro-inflammatory cyto-
kines, which could also increase the rate of HIV-1 infection [61]. Here, we also showed for the
first time that LA had no effect on the DC-SIGN (or Dendritic cell-specific ICAM-3 grabbing
non-integrin) receptor (Fig 3). DC-SIGN acts as a pathogen recognition receptor for viruses
and bacteria [62]. Some pathogens, such as HIV and HSV, are captured by DC-SIGN and mis-
use its function [63] so that they are subsequently transmitted to uninfected target cells [40,
45]. We could demonstrate that both viruses are dose-dependently inhibited by LA in
DC-SIGN-related cellular transmission pathways (Figs 3 and 5).
As LA is a highly negatively charged compound, it cannot cross the cellular membrane and
based on the HSV-2 time-of-drug addition experiments (Fig 4B) we believe that LA binds to
one or more envelope glycoproteins of HSV. These in vitro broad-spectrum antiviral activity
data indicate that LA acts as a dual HIV/HSV entry inhibitor (Figs 2 and 4) with equal potency
against both viruses. Another indication that LA targets the envelope proteins is the lack of
antiviral activity of LA against non-enveloped viruses such as the Picornaviridae Coxsackie
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type B4 and the Reoviridae Reovirus type 1 (>100 μg/ml or 12.5 μM; data not shown). These
findings are in accordance with those described for other polyanions [64].
Acyclovir has been described to possess anti-HIV activity by acting as an reverse transcrip-
tase inhibitor in herpes virus negative cells [13]. Other research groups found such inhibitory
activity only when certain herpes viruses were already present and pre-established an infection
in CD4+ T cells [12]. The lack of activity of acyclovir against HIV in our experimental co-
-infection model could be explained by the fact that we infected the CD4+ T cells with both
viruses simultaneously. However, these inconsistent data of acyclovir on HIV inhibition, ren-
dering it not an ideal molecule for microbicidal applications, unless used in combination with
other anti-HIV agents. Therefore, we investigated LA in combination with other antiviral
inhibitors. Additive to moderate synergistic effects were observed against HSV-2 infections
with PRO2000, acyclovir and the recently described potent lantibiotic HIV/HSV peptide inhib-
itor LabyA1 [31]. Additivity to synergy was observed with maraviroc and tenofovir against
HIV-1 replication, while antagonistic to additive effects were observed with PRO2000. This
discrepancy between synergy and antagonism with the LA/PRO2000 combination, could be
explained by the differences in envelope glycoproteins of HIV and HSV and the cross-resis-
tance profiles of both polyanions to HIV (Fig 11). To date, tenofovir, applied as a 1% vaginal
gel, still is the only drug that significantly inhibited HIV-1 transmission by 39% overall and of
HSV-2 by 51% and this even at suboptimal concentrations [8]. The potent inhibitory activity
against HIV and HSV-2, together with the observed synergy (and additivity) with tenofovir
and other anti-HIV and anti-HSV drugs, makes us believe that LA is a strong microbicide can-
didate. Especially, as Agarwal and colleagues demonstrated also the feasibility of conjugating
chemically nucleoside reverse transcriptase inhibitors with cellulose sulfate, displaying antiviral
and contraceptive properties [65].
In addition, cellulose sulfate, which failed throughout clinical microbicide trials, and poly-
styrene sulfonate combine antiviral activity against HIV-1 and HSV-2 with contraceptive activ-
ity [66]. Tollner et al., [67, 68] demonstrated that LA also exhibits contraceptive properties as
in vitro fertilization of macaque oocytes was blocked when sperm was treated before or after
capacitation. Importantly, LA (Fig 9), as well as polystyrene sulfonate, did not harm the vaginal
microbiota, but the anti-HIV activity of polystyrene sulfonate was not so potent, indicating
superior microbicidal properties for LA [69]. As a vaginal or rectal microbicide may not be
toxic nor stimulate HIV target cells, we showed that LA did not activate PBMCs, nor increased
their susceptibility for HIV-1 infection as our control agents tenofovir, PRO2000 or acyclovir
(Fig 7). In contrast, application and removal of cellulose sulfate and carrageenan, resulted in an
enhanced subsequent HIV-1 infection in vitro [70]. Further studies pointed out that cellulose
sulfate altered the epithelial architecture by affecting junctional proteins (e.g. zona occludens 1
(ZO-A1)) [71, 72]. Interestingly, Qui et al., mentioned that a water-soluble sulfonated lignin
had no effects on the epithelial integrity on different epithelial monolayers [18]. Previously
described in vitro and in vivo data demonstrated a good safety profile of PRO2000 [73, 74].
Our in vivo experiments in mice indicated that LA did not show superiority over acyclovir in
suppressing HSV-2 infection, however LA demonstrated a significant antiviral effect compara-
ble with tenofovir [9]. We could state, for the first time, that LA demonstrated an anti-HSV-2
activity in vivo, evaluating its effect on lesion viral titers (Fig 6). However, the more moderate
anti-herpetic activity in vivo, compared to its potency in vitro could be attributed to the admin-
istration route or its formulation. Previous studies in mice, using vaginally applied PRO2000 in
solution and a gel-formulation, demonstrated protective effects to genital HSV-2 infection
[75]. Further optimizations of in vivo studies are planned in the near future using a gel-contain-
ing LA preparation.
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In conclusion, these in vitro and in vivo results of inhibition of HIV and HSV transmission
and infection by LA, together with its high scale availability and safety profile, make it a very
promising microbicidal candidate.
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S2 Table. Virus inactivation of the laboratory-adapted NL4.3 strain in MT-4 cells.  
 
 
product 200 pg virus/well 100 pg virus/well 20 pg virus/well 
concentration product/well % block concentration product/well % block concentration product/well % block 
LA low 200 ng/ml 0 100 ng/ml 4 20 ng/ml 41 
40 ng/ml 1 20 ng/ml 2 4 ng/ml 51 
8 ng/ml 1 4 ng/ml 0 0.8 ng/ml 26 
PRO-2000 200 ng/ml 7 100 ng/ml 18 20 ng/ml 82 
40 ng/ml 2 20 ng/ml 6 4 ng/ml 40 
8 ng/ml 0 4 ng/ml 0 0.8 ng/ml 26 
HHA 200 ng/ml 34 100 ng/ml 51 20 ng/ml 68 
40 ng/ml 7 20 ng/ml 9 4 ng/ml 37 
8 ng/ml 5 4 ng/ml 1 0.8 ng/ml 7 
Aldrithiol 200 ng/ml 75 100 ng/ml 87 20 ng/ml 96 
40 ng/ml 50 20 ng/ml 71 4 ng/ml 89 
8 ng/ml 2 4 ng/ml 2 0.8 ng/ml 22 
	 1
Supporting Information PLoS ONE (Gordts SC et al.)  
 
The Low-cost Compound Lignosulfonic Acid (LA) Exhibits Broad-
spectrum Anti-HIV and Anti-HSV Activity and has Potential for 
Microbicidal Applications. 
 
Short title: Dual Anti-HIV and Anti-HSV Activity of LA. 
 
Stephanie C. Gordts 1#, Geoffrey Férir 1#, Thomas D’huys1, Mariya I. Petrova2,3, Sarah 
Lebeer2,3, Robert Snoeck1, Graciela Andrei1, Dominique Schols1*. 
	 2
Supporting Information 
S1 Table. Lactobacillus strains used in this study. 
Strain Relevant genotype/description reference/source 
Gastrointestinal Lactobacillus strains 
L. rhamnosus GG 
(ATCC 53103) 
Wild-type, fecal isolate [1] 
Vaginal Lactobacillus strains 
L. rhamnosus GR-1 
ATCC 55826 
Wild-type, female urethra isolate  [2,3], ATCC 
L. reuteri RC-14  
ATCC 55845 
Wild-type, female vaginal isolate  [4,5], ATCC 
L. crispatus  
NCIMB 4505 
Wild-type, human vaginal isolate  [6], LMG/BCCM 
L. jensenii  
ATCC 25258 
Wild-type, human vaginal isolate [7], LMG/BCCM  
L. gasseri  
ATCC 33323 
Wild-type, human vaginal isolate  [8], LMG/BCCM  
L. helveticus  
LG0301 
Wild-type, human vaginal isolate Mario Van Eechoutte Laboratory 
Bacteriology Research, UGent  
L. helveticus  
LG0373 
Wild-type, human vaginal isolate Mario Van Eechoutte Laboratory 
Bacteriology Research, UGent  
L. plantarum  
CMPG5300 
Wild-type, human vaginal isolate [9] 
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Fig S2. HIV-1 binding to the cell surface of CD4+ T-cells in the presence of LA. SupT1 
cells were incubated with a high amount of HIV-1 NL4.3 virus (positive untreated control) and 
combined with or without compounds for 2 hours at RT.  Thereafter, cells were extensively 
washed and gp120 binding was evaluated in all the virus treated conditions with the anti-
human 2G12 mAb + RaH-IgG-FITC. The bars represent the percentages of anti-gp120 
binding relative to the positive control (d). Each value represents the mean ± SEM of 3 
independent experiments. * p<0.05, ** p<0.01, *** p<0.005, *** p<0.001  compared to the 
nontreated control, according to the one-way Anova and Dunnett’s multi comparison post-
hoc test.  
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S1 Fig. Specific cell markers for monocyte-derived dendritic cells (MDDCs). The 
indicated cell surface markers highlight the purity of the MDDC population used in our 
experiments. The white histograms show the background fluorescence. The filled grey 
histograms indicate the expression levels of six cell surface markers, specific for MDDCs 
after treatment with the growth factors IL-4 and GM-CSF. 
 
